By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eleven Biotherapeutics 

215 First Street
Suite 400
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-871-9911 Fax: 617-858-0911


Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.




Founder: Reza Dana, K. Christopher Garcia, Greg Verdine, Casey Weaver, K. Dane Wittrup

CEO: Abbie Celniker

CMO (Medical): Michael Goldstein


Please click here for Eleven Biotherapeutics.

Key Statistics

Ownership: Public

Web Site: Eleven Bio
Symbol: EBIO


Company News
Eleven Bio (EBIO) Reports Second Quarter 2017 Financial Results 8/14/2017 6:44:41 AM
Eleven Bio (EBIO) To Report Second Quarter 2017 Financial Results On Monday, August 14, 2017 8/7/2017 9:49:39 AM
Eleven Bio (EBIO) To Present At Canaccord Genuity 37th Annual Growth Conference 8/4/2017 7:43:55 AM
Eleven Bio (EBIO) To Collaborate With AstraZeneca PLC (AZN) And NCI On Development Of Viciniumtm In Combination With Durvalumab For The Treatment Of Non-Muscle Invasive Bladder Cancer 6/6/2017 6:48:54 AM
Eleven Bio (EBIO) Announces Data And Safety Monitoring Board (DSMB) Recommendation To Continue Phase III Registration Trial With Vicinium In Non-Muscle Invasive Bladder Cancer Based On Review Of Safety And Efficacy Data 6/1/2017 6:23:48 AM
Eleven Bio (EBIO) Continues Expansion Of Clinical Development Team With Appointment Of David Brooks, M.D., Ph.D., To Senior Vice President, Clinical Development 5/17/2017 8:27:22 AM
Eleven Bio (EBIO) Reports First Quarter 2017 Financial Results 5/4/2017 6:32:41 AM
Eleven Bio (EBIO) To Report First Quarter 2017 Financial Results On Thursday, May 4, 2017 4/28/2017 7:43:19 AM
Eleven Bio (EBIO) Presents New Preclinical Data At AACR Supporting The Potential Of The Company’s Locally- And Systematically-Administered Drug Candidates 4/3/2017 10:43:04 AM
Eleven Bio (EBIO) To Present New Preclinical Data At AACR Annual Meeting 2017 3/27/2017 6:14:47 AM